Clinical Trials
6
Trial Phases
3 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
- Conditions
- Central Line Associated Blood Stream Infections (CLABSI)
- Interventions
- Drug: (taurolidine and heparin) catheter lock solution
- First Posted Date
- 2025-02-12
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- CorMedix
- Target Recruit Count
- 200
- Registration Number
- NCT06822426
- Locations
- 🇺🇸
Johns Hopkins Clinical Research Unit, Baltimore, Maryland, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age
- Conditions
- Catheter-Related Infections
- Interventions
- Drug: (taurolidine and heparin) catheter lock solutionDrug: Standard of Care
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- CorMedix
- Target Recruit Count
- 36
- Registration Number
- NCT06714864
- Locations
- 🇺🇸
Children's of Alabama/University of Alabama, Birmingham, Alabama, United States
🇺🇸Stanford, Palo Alto, California, United States
🇺🇸Nemours Children's Hospital - DE, Wilmington, Delaware, United States
Expanded Access Program for Patients At Risk for Catheter-related Infections Who Are Not Eligible for DefenCath® Clinical Trials
- Conditions
- Catheter-related Bloodstream Infection
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- CorMedix
- Registration Number
- NCT06707480
Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection
- Conditions
- Kidney Failure, ChronicCatheter-Related Infections
- Interventions
- First Posted Date
- 2016-01-11
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- CorMedix
- Target Recruit Count
- 806
- Registration Number
- NCT02651428
- Locations
- 🇺🇸
Riverside Nephrology Physicians/Van Buren Dialysis center, Riverside, California, United States
🇺🇸North America Research Institute, San Dimas, California, United States
🇺🇸North Beach Dialysis Center Inc., Miami Gardens, Florida, United States
Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2020-08-24
- Lead Sponsor
- CorMedix
- Registration Number
- NCT01391520
- Prev
- 1
- 2
- Next
News
CorMedix Completes Phase III Enrollment for REZZAYO Antifungal Prophylaxis in Bone Marrow Transplant Patients
CorMedix announced completion of enrollment in the global Phase III ReSPECT trial evaluating REZZAYO (rezafungin) for preventing fungal infections in adult patients undergoing allogeneic blood and marrow transplantation.
CorMedix Makes $5 Million Strategic Investment in Talphera's Phase 3 Anticoagulant Program
CorMedix invested $5 million in Talphera as part of a $29 million private placement to fund completion of the Phase 3 NEPHRO CRRT study for Niyad, a breakthrough-designated anticoagulant.
CorMedix Acquires Melinta Therapeutics for $300 Million to Expand Anti-Infective Portfolio
CorMedix has entered a definitive agreement to acquire Melinta Therapeutics for $300 million, adding seven marketed infectious disease products to its portfolio.
CorMedix Announces Positive Preliminary Q4 2024 Results and Business Updates
CorMedix reported preliminary unaudited net revenue of approximately $31 million for Q4 2024 and $43 million for FY 2024, exceeding previous guidance.